CA3010771A1 - Polytherapie comprenant compose de fer et compose de citrate - Google Patents

Polytherapie comprenant compose de fer et compose de citrate Download PDF

Info

Publication number
CA3010771A1
CA3010771A1 CA3010771A CA3010771A CA3010771A1 CA 3010771 A1 CA3010771 A1 CA 3010771A1 CA 3010771 A CA3010771 A CA 3010771A CA 3010771 A CA3010771 A CA 3010771A CA 3010771 A1 CA3010771 A1 CA 3010771A1
Authority
CA
Canada
Prior art keywords
compound
iron
combination therapy
citrate
sfp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3010771A
Other languages
English (en)
Inventor
Ajay Gupta
Gary BRITTENHAM
Raymond Pratt
Vivian H. Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockwell Medical Inc
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of CA3010771A1 publication Critical patent/CA3010771A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

L'invention concerne une polythérapie comprenant un composé de fer, de préférence le pyrophosphate ferrique soluble (SFP), en combinaison avec un composé de citrate. L'invention concerne également des procédés d'utilisation de la polythérapie dans le traitement de carence en fer, avec ou sans anémie, y compris l'anémie ferriprive réfractaire au traitement par le fer et d'autres syndromes de séquestration de fer, et des compositions pharmaceutiques et des kits comprenant SFP ou un autre composé de fer et un composé de citrate.
CA3010771A 2016-01-06 2017-01-05 Polytherapie comprenant compose de fer et compose de citrate Abandoned CA3010771A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662275487P 2016-01-06 2016-01-06
US62/275,487 2016-01-06
US201662432564P 2016-12-09 2016-12-09
US62/432,564 2016-12-09
PCT/US2017/012300 WO2017120311A1 (fr) 2016-01-06 2017-01-05 Polythérapie comprenant composé de fer et composé de citrate

Publications (1)

Publication Number Publication Date
CA3010771A1 true CA3010771A1 (fr) 2017-07-13

Family

ID=57963442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010771A Abandoned CA3010771A1 (fr) 2016-01-06 2017-01-05 Polytherapie comprenant compose de fer et compose de citrate

Country Status (5)

Country Link
EP (1) EP3399970A1 (fr)
JP (1) JP2019501184A (fr)
CN (1) CN108883085A (fr)
CA (1) CA3010771A1 (fr)
WO (1) WO2017120311A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735238A4 (fr) * 2018-01-02 2021-11-03 Kashiv Biosciences, LLC Composition pharmaceutique orale stable de citrate ferrique
CN112457350A (zh) * 2020-11-30 2021-03-09 中国大冢制药有限公司 一种枸橼酸焦磷酸铁络合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
JP4655338B2 (ja) * 2000-07-06 2011-03-23 大正製薬株式会社 鉄欠乏性貧血改善のための薬剤
US7857977B2 (en) 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
US7816404B2 (en) 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
US20150320091A1 (en) * 2012-05-08 2015-11-12 Dsm Ip Assets B.V. Iron supplementation of rice kernels
EP2842434A1 (fr) * 2013-08-28 2015-03-04 DSM IP Assets B.V. Supplément de fer d'un bouillon concentré

Also Published As

Publication number Publication date
CN108883085A (zh) 2018-11-23
JP2019501184A (ja) 2019-01-17
WO2017120311A1 (fr) 2017-07-13
EP3399970A1 (fr) 2018-11-14

Similar Documents

Publication Publication Date Title
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
WO2017173415A3 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
WO2018067512A8 (fr) Composés spirocycliques
WO2015070224A3 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
WO2015160975A3 (fr) Polythérapies
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
WO2016149501A3 (fr) Agents thérapeutiques modifiés et compositions associées
WO2017027757A3 (fr) Vaccin antivariolique pour le traitement du cancer
PH12019502197A1 (en) Macrocyclic compound and uses thereof
WO2017027359A8 (fr) Pyridines et leur utilisation dans le traitement du cancer
EP3860621A4 (fr) Formulations de fer pour administration topique et procédés de traitement d'une déficience en fer
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
WO2019099646A8 (fr) Composés macrocycliques et utilisations de ces composés
MX2020000135A (es) Nuevos compuestos de quinolinona.
WO2017187343A3 (fr) Nanoémulsions et méthodes pour la cancérothérapie
WO2015181624A3 (fr) Dérivés de nucléosides pour le traitement du cancer
WO2016130581A3 (fr) Polythérapie anticancéreuse
WO2016181220A3 (fr) Compositions thérapeutiques et méthodes d'utilisation de ces compositions
WO2015106215A3 (fr) Compositions pharmaceutiques comprenant le 15-hepe et méthodes de traitement de l'asthme et de pathologies pulmonaires à l'aide desdites compositions
WO2015112705A3 (fr) Combinaisons thérapeutiques pour le traitement du cancer
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2017121646A8 (fr) Dérivés de 3-(carboxyéthyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-décane
WO2019043176A3 (fr) Inhibiteur de l'histone-désacétylase en association avec un agent antimétabolite pour la cancérothérapie
PH12020500079A1 (en) Novel substituted xanthine derivates

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831